These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17660494)

  • 1. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
    Lorenzen S; Hentrich M; Haberl C; Heinemann V; Schuster T; Seroneit T; Roethling N; Peschel C; Lordick F
    Ann Oncol; 2007 Oct; 18(10):1673-9. PubMed ID: 17660494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
    Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
    Alici S; Buyukberber S; Alkis N; Benekli M; Ozkan M; Bilici A; Demirci U; Karaca H; Arpaci E; Gumus M; Altunbas M; Dane F; Turk HM;
    Asian Pac J Cancer Prev; 2013; 14(1):423-7. PubMed ID: 23534766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
    Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J
    Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
    J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
    Unek IT; Akman T; Oztop I; Unal OU; Salman T; Yilmaz U
    Gastric Cancer; 2013 Jul; 16(3):428-34. PubMed ID: 23086560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
    Deleporte A; Van den Eynde M; Forget F; Holbrechts S; Delaunoit T; Houbiers G; Kalantari HR; Laurent S; Vanderstraeten E; De Man M; Vergauwe P; Clausse M; Van Der Auwera J; D'Hondt L; Pierre P; Ghillemijn B; Covas A; Paesmans M; Ameye L; Awada A; Sclafani F; Hendlisz A
    Cancer Med; 2021 Jul; 10(13):4366-4374. PubMed ID: 34057299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
    Ferri LE; Ades S; Alcindor T; Chasen M; Marcus V; Hickeson M; Artho G; Thirlwell MP
    Ann Oncol; 2012 Jun; 23(6):1512-7. PubMed ID: 22039085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
    Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.